{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "NCT04179760",
            "NStudiesAvail": 430269,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "BriefSummary",
                  "BriefTitle",
                  "CentralContactEMail",
                  "CentralContactName",
                  "CentralContactPhone",
                  "CentralContactPhoneExt",
                  "CentralContactRole",
                  "CollaboratorClass",
                  "CollaboratorName",
                  "CompletionDate",
                  "CompletionDateType",
                  "Condition",
                  "ConditionAncestorId",
                  "ConditionAncestorTerm",
                  "ConditionBrowseBranchAbbrev",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "BriefSummary": [
                              "This study consists of two phases (Phase I and Phase II). Phase II will be conducted sequentially after the safety of SCM-AGH is secured in Phase I.\n\nPhase I: Multicenter in Korea, Randomized, Open-label, Parallel arm Phase II: Multicenter in Korea, Double-blind, Placebo-controlled, Parallel arm"
                        ],
                        "BriefTitle": [
                              "Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis"
                        ],
                        "CentralContactEMail": [
                              "hher@scmlifescience.com"
                        ],
                        "CentralContactName": [
                              "Howard Her"
                        ],
                        "CentralContactPhone": [
                              "+8200000000"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "December 30, 2022"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Dermatitis, Atopic"
                        ],
                        "ConditionAncestorId": [
                              "D000012871",
                              "D000012873",
                              "D000030342",
                              "D000017443",
                              "D000006969",
                              "D000006967",
                              "D000007154"
                        ],
                        "ConditionAncestorTerm": [
                              "Skin Diseases",
                              "Skin Diseases, Genetic",
                              "Genetic Diseases, Inborn",
                              "Skin Diseases, Eczematous",
                              "Hypersensitivity, Immediate",
                              "Hypersensitivity",
                              "Immune System Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC16",
                              "BC17",
                              "BC20",
                              "All"
                        ],
                        "NCTId": [
                              "NCT04179760"
                        ]
                  },
                  {
                        "Rank": 2,
                        "BriefSummary": [
                              "This is a long-term safety follow-up study of the Phase I/II multicenter study of SCM-AGH in subjects with moderate to severe atopic dermatitis. subjects will be followed up for a maximum period of 240 weeks after the first dose of investigational product. Only subjects previously enrolled in protocol ADT2002 (ClinicalTrials.gov ID: NCT04179760) will be eligible for this long-term follow-up protocol."
                        ],
                        "BriefTitle": [
                              "Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials"
                        ],
                        "CentralContactEMail": [],
                        "CentralContactName": [],
                        "CentralContactPhone": [],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "March 31, 2025"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Dermatitis, Atopic"
                        ],
                        "ConditionAncestorId": [
                              "D000012871",
                              "D000012873",
                              "D000030342",
                              "D000017443",
                              "D000006969",
                              "D000006967",
                              "D000007154"
                        ],
                        "ConditionAncestorTerm": [
                              "Skin Diseases",
                              "Skin Diseases, Genetic",
                              "Genetic Diseases, Inborn",
                              "Skin Diseases, Eczematous",
                              "Hypersensitivity, Immediate",
                              "Hypersensitivity",
                              "Immune System Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC16",
                              "BC17",
                              "BC20",
                              "All"
                        ],
                        "NCTId": [
                              "NCT04185584"
                        ]
                  }
            ]
      }
}